Handheld Devices Lead Growth of Detection Devices in Biodefense Pathogen ID Market

August 14, 2015

Wellesley, Mass., August 14, 2015 – Demand for point-of-use devices will accelerate the growth of handheld devices in the U.S. market for biodefense-related rapid pathogen identification and treatments. BCC Research reveals in its new report that the majority of devices used for rapid detection are handheld readers with the ability to read various assays, either by individual pathogen or with several pathogens in one test.

The U.S. market for rapid identification/sensing products is projected to grow from $248 billion in 2016 to $364 billion in 2021, reflecting a five-year compound annual growth rate of 8%.

The report outlines the political and social landscape of biodefense, focusing on the issues of surveillance, coordination of resources and financing. Additionally, government funding, as well as industry and university funding of biodefense projects, is discussed.

Pathogenic agents can be viruses, bacteria, fungi, protozoa, parasites, or manufactured toxins. They are able to cause diseases in plants, animals and humans. Pathogens that are harmful to animals and plants are not covered in this report unless they pose eminent danger to humans through consumption.

The market for biodefense-related rapid pathogen identification products continues to expand with an emphasis on products that are more portable, easy to use, sensitive and accurate. Multiple assays are being field-tested and used by military personnel, first responders, industry and businesses.

“The need for rapid identification has expanded the market for handheld assay devices that can accurately determine if a pathogen is present and its composition,” says BCC Research analyst Peggy S. Lehr. “Evolving technology can determine the amount of pathogen present. The handheld assay market holds the largest share of the detection market, followed by portable units and then stationary units.”

The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments (BIO145A), which focuses on the U.S. biodefense-related rapid pathogen identification and treatment markets, provides an overview of the industry and its participants. It also projects the growth of the market through 2021, with analysis of trends and emerging technologies pertinent to biological rapid pathogen identification.

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.

The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments( BIO145A )
Publish Date: Aug 2015    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.